Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Accumulated Expenses: 2014-2025

Historic Other Accumulated Expenses for ImmunityBio (IBRX) over the last 10 years, with Sep 2025 value amounting to $2.1 million.

  • ImmunityBio's Other Accumulated Expenses rose 49.93% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 49.93%. This contributed to the annual value of $1.1 million for FY2024, which is 46.65% up from last year.
  • Latest data reveals that ImmunityBio reported Other Accumulated Expenses of $2.1 million as of Q3 2025, which was up 8.90% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Other Accumulated Expenses peaked at $2.9 million during Q1 2022, and registered a low of $556,000 during Q1 2024.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $1.1 million (2024), whereas its average is $1.3 million.
  • As far as peak fluctuations go, ImmunityBio's Other Accumulated Expenses crashed by 74.16% in 2021, and later surged by 376.80% in 2025.
  • Over the past 5 years, ImmunityBio's Other Accumulated Expenses (Quarterly) stood at $2.6 million in 2021, then tumbled by 37.26% to $1.6 million in 2022, then tumbled by 56.02% to $716,000 in 2023, then soared by 46.65% to $1.1 million in 2024, then spiked by 49.93% to $2.1 million in 2025.
  • Its Other Accumulated Expenses stands at $2.1 million for Q3 2025, versus $1.9 million for Q2 2025 and $2.7 million for Q1 2025.